Cargando…

Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer

Background: Everolimus is one of the key drugs for the treatment of advanced breast cancer. The optimal target concentration range for everolimus therapy in patients with breast cancer has not yet been established. This study aimed to characterize everolimus pharmacokinetics (PK) and determine the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirabatake, Masaki, Mizuno, Tomoyuki, Kato, Hironori, Hashida, Tohru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520775/ https://www.ncbi.nlm.nih.gov/pubmed/36188563 http://dx.doi.org/10.3389/fphar.2022.984002

Ejemplares similares

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
por: Tohi, Makiko, et al.
Publicado: (2023)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
por: de Wit, D., et al.
Publicado: (2016)

Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication
por: Tanaka, Fumiaki, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

A simplified method for therapeutic drug monitoring of mitotane by gas chromatography‐electron ionization‐mass spectrometry
por: Ando, Motozumi, et al.
Publicado: (2020)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database
por: Satake, Riko, et al.
Publicado: (2021)

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib
por: Ikesue, Hiroaki, et al.
Publicado: (2022)

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
por: Pascual, Tomas, et al.
Publicado: (2017)

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
por: Yamaoka, Kenta, et al.
Publicado: (2023)

Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles
por: Labriffe, Marc, et al.
Publicado: (2022)

Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV
por: von Kleist, Max, et al.
Publicado: (2020)

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
por: Kato, Koki, et al.
Publicado: (2022)

Insights into the pharmacodynamics and pharmacokinetics of meldonium after exposure to acute high altitude
por: Liu, Fengying, et al.
Publicado: (2023)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
por: Tamura, Ryo, et al.
Publicado: (2023)

Integration Analysis of Pharmacokinetics and Metabolomics to Predict Metabolic Phenotype and Drug Exposure of Remdesivir
por: Du, Ping, et al.
Publicado: (2022)

Population Pharmacokinetics of Colistin Sulfate in Critically Ill Patients: Exposure and Clinical Efficacy
por: Yu, Xu-ben, et al.
Publicado: (2022)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
por: Zhang, Miao, et al.
Publicado: (2022)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Pharmacokinetics of Acetaminophen and Metformin Hydrochloride in Rats After Exposure to Simulated High Altitude Hypoxia
por: Zhu, Jun-bo, et al.
Publicado: (2021)

Commentary: Population pharmacokinetics of colistin sulfate in critically ill patients: Exposure and clinical efficacy
por: Chen, Huadong, et al.
Publicado: (2022)

Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system
por: Jiang, Jing, et al.
Publicado: (2013)

Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
por: Yagishita, Hironobu, et al.
Publicado: (2022)

Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding
por: Garessus, Estella Dora Germaine, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Advances in Chemical Constituents, Clinical Applications, Pharmacology, Pharmacokinetics and Toxicology of Erigeron breviscapus
por: Wu, Ruixia, et al.
Publicado: (2021)

Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version
por: Xie, Jiaxi, et al.
Publicado: (2022)

Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results
por: Ruiz-Falcó Rojas, María Luz, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
por: Kubota, Ryuji, et al.
Publicado: (2018)

Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine
por: Zheng, Liang, et al.
Publicado: (2022)

Estimation of Mycophenolic Acid Exposure in Heart Transplant Recipients by Population Pharmacokinetic and Limited Sampling Strategies
por: Wang, Xipei, et al.
Publicado: (2021)

Machine learning advances the integration of covariates in population pharmacokinetic models: Valproic acid as an example
por: Zhu, Xiuqing, et al.
Publicado: (2022)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2020)

The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study
por: Du, Xiaohuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g0kefumhiqvfk19ulolrf48bbd